Increased tyrosine kinase activity of abl oncogene in Philadelphia chromosome positive-leukemic cells leads to activation of p21 ras and phosphatidylinositol 3'-kinase (PI 3-Kinase). The mechanism of activation of these signaling pathways is not understood, but numerous studies have focused on the identi®cation and characterization of downstream substrates of BCR/abl tyrosine kinase as potential mediators of oncogenic signaling. It was recently found that the 120 kDa protein product of the c-cbl proto-oncogene is highly tyrosine phosphorylated and associates with BCR/abl in transformed hematopoietic cells. We have characterized further cbl's involvement in BCR/abl mediated tumorigenesis using growth factor independent BCR/abl transformed BaF3 cells. Our experiments show that, in contrast to other cell types, the in vivo interaction of cbl with GRB2 and p85 is signi®cantly enhanced in BCR/abl transformed BaF3 cells and that tyrosine phosphorylation of cbl leads to a direct interaction with GRB2, p85 and abl SH2 domains. A 14-fold increase in cbl associated PI 3-kinase activity in BCR/abl transformed cells suggests that the binding of p85 SH2 domains to tyrosine phosphorylated cbl may contribute to PI 3-kinase activation. Domain analysis studies indicate that both SH3 domains of GRB2 bind to the proline rich region of cbl in quiescent BaF3 cells, whereas GRB2 SH2 domain interacts with a non-contiguous sequence of cbl in transformed cells. Although the interaction of cbl with GRB2 in transformed cells was facilitated by binding of GRB2 to BCR/abl, phosphorylation of cbl and its interaction with p190 BCR/abl remained unaltered in BaF3 cells transformed by p190Y177F BCR/abl mutant which is unable to bind GRB2. The current information and the data presented here suggest that, although cbl lacks src homology domains, it represents a novel intermediate protein which, by interaction with key SH-containing adaptor proteins, may participate in regulation of the Ras and PI 3-kinase pathways in BCR/abl transformed hematopoietic cells.
Increased tyrosine kinase activity of abl oncogene in Philadelphia chromosome positive-leukemic cells leads to activation of p21 ras and phosphatidylinositol 3'-kinase (PI 3-Kinase). The mechanism of activation of these signaling pathways is not understood, but numerous studies have focused on the identi®cation and characterization of downstream substrates of BCR/abl tyrosine kinase as potential mediators of oncogenic signaling. It was recently found that the 120 kDa protein product of the c-cbl proto-oncogene is highly tyrosine phosphorylated and associates with BCR/abl in transformed hematopoietic cells. We have characterized further cbl's involvement in BCR/abl mediated tumorigenesis using growth factor independent BCR/abl transformed BaF3 cells. Our experiments show that, in contrast to other cell types, the in vivo interaction of cbl with GRB2 and p85 is signi®cantly enhanced in BCR/abl transformed BaF3 cells and that tyrosine phosphorylation of cbl leads to a direct interaction with GRB2, p85 and abl SH2 domains. A 14-fold increase in cbl associated PI 3-kinase activity in BCR/abl transformed cells suggests that the binding of p85 SH2 domains to tyrosine phosphorylated cbl may contribute to PI 3-kinase activation. Domain analysis studies indicate that both SH3 domains ofIntroduction Protein-protein interactions are critical in regulating many cellular responses. Recent work has identi®ed several small protein domains which modulate protein binding in a wide variety of cellular contexts. These include Src homology 2 (SH2), Src homology 3 (SH3) and Phosphotyrosine binding (PTB) domains (Cohen et al., 1995; Kavanaugh et al., 1995; Pawson and Gish, 1992; Weng et al., 1995) . The SH3 mediated interactions are constitutive, whereas phosphorylation of speci®c tyrosine residues determines the interactions with SH2 domains. The best understood mechanism of signal transduction is the activation of transmembrane receptors and src oncogene family protein tyrosine kinases which initiate phosphorylation of intracellular substrates. Substrate interactions with protein-tyrosine kinases occur at the plasma membrane in adherent cells and mutations of the N-terminal myristoylation site of v-src or v-abl tyrosine kinases abolish their transforming capacity due to presumed impaired association with the plasma membrane (Kamps et al., 1985) .
The chimeric BCR/abl oncogene is generated from a reciprocal translocation between chromosome 9 and 22 and the in-frame fusion of BCR sequences upstream of c-abl results in generation of chimeric p210 or p190 products (Daley and Ben-Neriah, 1991; Groen et al., 1984; Voncken et al., 1995) . The 210 and 190 kDa BCR/abl proteins associated with chronic myelogenous and acute leukemias, respectively, are cytoplasmic oncogenes with deregulated tyrosine kinase activity and transforming properties for hematopoietic cells (Cortez et al., 1995; Lugo et al., 1990) . The mechanism of BCR/abl-mediated transformation of hematopoietic cells is not fully understood but involves activation of at least two signaling pathways; p21 ras and Phosphatidylinositol 3-kinase (PI 3-kinase) (Mandanas et al., 1993; Varticovski et al., 1991) . In addition, activation of JunK and Stat 1 and 5 downstream targets have been reported in BCR/abl transformed cells Frank and Varticovski, 1996; Ilaria and Van Etten, 1996; Raitano et al., 1995) . A direct interaction of BCR/abl with GRB2/mSOS complex could provide a mechanism for activation of the Ras pathway and is required for transformation of ®broblasts but not hematopoietic cells (Goga et al., 1995; Pendergast et al., 1993) . The mechanism of PI 3-kinase activation in BCR/abl-induced transformed cells is not known (Skorski et al., 1995; Varticovski et al., 1991) but does not require direct binding of p85 SH2 domains to BCR/abl (Jain et al., 1996) .
Mammalian PI 3-kinase is a heterodimeric protein comprising a 85 kDa regulatory subunit (p85), which contains one SH3 and two SH2 domains, and a 110 kDa catalytic subunit (p110) (Carpenter et al., 1990; Hiles et al., 1992) . PI 3-kinase is a downstream target necessary for BCR/abl mitogenic signaling (Skorski et al., 1995) . The most ecient mechanism for PI 3-kinase activation involves occupancy of p85 SH2 domains by phosphorylated YXXM motifs Rordorf-Nikolic et al., 1995) . Although p85 SH2 domains bind to the YXXM motif in p210 BCR/abl, abrogation of this interaction does not impair PI 3-kinase activation or BCR/abl induced growth factor independence of hematopoietic cells (Carlesso et al., 1994; Jain et al., 1996) . Therefore, binding of p85 SH2 domains to other tyrosine phosphorylated protein(s) may regulate PI 3-kinase activity in BCR/abl transformed hematopoietic cells.
Much attention has been focused on the characterization of intracellular substrates of BCR/abl tyrosine kinase. It was recently found that the 120 kDa protein product of the c-cbl protooncogene is highly tyrosine phosphorylated in v-abl transformed murine fibroblasts and in BCR/abl transformed human hematopoietic cells (Andoniou et al., 1994; Sattler et al., 1996) . The cbl gene was discovered as the cellular homologue of the v-cbl oncogene which transforms early B-cells and myeloid cells (Langdon et al., 1989) . Although the primary structure of c-cbl resembles that of a transcription factor, its physiological function has yet to be determined (Blake et al., 1991 (Blake et al., , 1993 . Recent studies reveal that cbl is tyrosine phosphorylated following activation of many receptors and interacts with SH2 and SH3 domain-containing proteins suggesting that cbl may be an important component of signal transduction downstream of tyrosine kinases (Donovan et al., 1994; Fukazawa et al., 1995; Galisteo et al., 1995; Kotani et al., 1995; Meisner et al., 1995; Odai et al., 1995; Wang et al., 1996) . Evidence that cbl plays a role in regulating signals mediated by protein tyrosine kinases has also originated from genetic studies in C. elegans (Yoon et al., 1995) . These studies identi®ed the cbl homologue, sli-1, as a negative regulator of the Let-23 receptor tyrosine kinase.
The objective of the present study was to examine the role of p120 cbl in BCR/abl-induced transformation of hematopoietic cells by analysis of mechanisms of interaction with key adaptor proteins of the Ras and PI 3-kinase pathways. We report here that, in BCR/abl transformed BaF3 cells, p120
cbl is a major tyrosine phosphorylated protein and that tyrosine phosphorylation of cbl leads to an increase in association with GRB2 and p85 by mechanisms which dier from interactions with these adaptor proteins in other cell types. In addition, anti-P-Tyr, GRB2 and cbl immune complexes contained an increase in PI 3-kinase activity in transformed cells.
Results

p120
cbl is a major tyrosine phosphorylated protein in BCR/abl transformed BaF3 cells BCR/abl induced transformation and activation of downstream targets is dependent on the expression of active abl tyrosine kinase (Chung and Wong, 1995; Varticovski et al., 1991) . Analysis of tyrosine phosphorylated proteins in p210 BCR/abl transformed BaF3 cells is shown in Figure 1a . In addition to autophosphorylated 210 kDa BCR/abl gene product, proteins of 120 and 52 ± 40 kDa are the major tyrosine phosphorylated proteins. A similar pattern of tyrosine phosphorylated proteins was observed during transient expression of a temperature-sensitive mutant of p210 BCR/abl in BaF3 cells (Jain et al., 1996) . We recently reported that the 52 and 46 kDa proteins are tyrosine phosphorylated isoforms of adaptor protein, Shc (Harrison-Findik et al., 1995) . While we were attempting to identify pp120, it was reported that the 120 kDa protein product of the c-cbl protooncogene is tyrosine phosphorylated in K562 cells, Abelson murine leukemia virus (A-MuLV) transformed NIH3T3 ®broblasts and in murine ABLS-8 pre-B lymphoma cells (Andoniou et al., 1994) . Therefore, we investigated whether the 120 kDa tyrosine phosphorylated protein in BCR/abl transformed BaF3 cells (Bp210 cells) is c-cbl. Whole cell lysates from parental and p210 BCR/abl transformed cells (Figure 1b , lanes 1 and 3) were immunoprecipitated with anti-cbl antibodies. Immunoprecipitates from parental and transformed cells (lanes 2 and 4, respectively), and immunodepleted cell lysate from Bp210 cells (lane 5) were resolved on SDS gel and analysed by immunoblotting with anti-P-Tyr antibodies. No signi®cant phosphorylation of p120 was observed in whole cell lysate or in anti-cbl immunoprecipitates from parental BaF3 cells (Figure 1b, lanes 1 and 2) . In contrast, prominent tyrosine phosphorylation of 120 kDa protein was detected in Bp210 cells (lane 3). This phosphoprotein was immunoprecipitated with anti-cbl antibodies (lane 4) and depleted from the supernatant (lane 5). Figure 1c shows that the expression of cbl was equivalent in parental and transformed cells. These results demonstrate that the prominent 120 kDa tyrosine phosphorylated protein in BCR/abl transformed BaF3 cells is encoded by protooncogene c-cbl. The primary structure of cbl reveals a large proline-rich region with 17 PXXP motifs including a known binding sequence PPVPPR (amino acid 494 ± 499) for the SH3 domain of GRB2. Constitutive interaction of cbl with GRB2 has been shown in Jurkat, Ramos and quiescent non-hematopoietic cells (Buday et al., 1996; Donovan et al., 1994; Meisner et al., 1995; . Activation of p21 ras has been described in BCR/abl transformed cells and in cells from patients with CML (Goga et al., 1995; Mandanas et al., 1993) . Since cbl is a major BCR/abl substrate in transformed hematopoietic cells, we sought to determine whether cbl associates with GRB2 in parental cells and whether this association is altered in BCR/abl transformed cells.
Cell lysates were immunoprecipitated with anti-GRB2 antibodies and the amount of cbl coprecipitated from parental and BCR/abl transformed cells was determined by immunoblotting with anti-cbl antibodies ( Figure 2a , top panel). In contrast to previous studies which reported no increase in interaction of GRB2 with cbl in response to T cell activation (Donovan et al., 1994; Fukazawa et al., 1995; Meisner et al., 1995) , we found a marked increase in the association of cbl with GRB2 in BCR/abl transformed cells (Figure 2a, lane 4) . Figure  2a , bottom panel shows that the same amount of GRB2 protein was immunoprecipitated from both cell lysates. The anti-GRB2 antibodies immunoprecipitated p120 cbl and three other prominent phosphoproteins as detected by anti-P-Tyr antibodies (Figure 2b ). These phosphoproteins were previously identi®ed as BCR/abl and the two forms of Shc (Goga et al., 1995; HarrisonFindik et al., 1995) .
We con®rmed the in vivo interaction of cbl with GRB2 in converse experiments analysing anti-cbl immune complexes from parental and BCR/abl transformed cells for the presence of GRB2 protein.
As seen in Figure 2c , we detected GRB2 in anti-cbl precipitates in quiescent parental cells which was increased in transformed cells. Taken together, these data suggest that GRB2 and cbl exist as a preformed complex in parental cells and that cbl is a GRB2-associated substrate in BCR/abl transformed cells.
Mechanisms of association of cbl with GRB2 in parental and transformed cells
To identify the domains of GRB2 and cbl involved in their interactions, we compared the binding anity of wt GST-GRB2 fusion protein with mutant GST-GRB2 proteins which have inactivating point mutations in one or both SH3 domains, or the SH2 domain. Cell lysates from parental (Figure 3a, upper panel) or BCR/ abl transformed cells (Figure 3a , lower panel) were incubated with Agarose beads containing GST alone ( Figure 3a , lane 2), wt or mutant GRB2 GST-fusion proteins. Bound proteins were analysed by immunoblotting with anti-cbl antibodies. Cbl associated with the wt and all mutant GRB2 proteins which lack functional N-terminal SH3, SH2 or the C-terminal SH3 domains in parental or transformed cells (lanes 3 ± 6, upper and lower panels) but not with GST alone (lane 2). Although no signi®cant dierences in binding to the mutant and wt GRB2 proteins was seen in this experiment, we detected higher binding to the wt GRB2 when less than 1 mg/mg of cell lysate protein of GST-fusion constructs were used for binding assays (not shown). Association of cbl with GRB2 36 mutant which lacks the functional N-terminal SH3 domain in parental cells suggests that the C-SH3 domain of GRB2 is sucient for binding to cbl. These results are in contrast with other studies which provided evidence that only the N-terminal SH3 domain of GRB2 binds to cbl. To verify the binding capacity of GRB2 fusion proteins, the same blots were probed with anti-Shc antibodies which showed Shc in association with all GRB2 constructs except GRB2 86 (not shown). In parental cells, cbl is neither phosphorylated nor associated with the GST-GRB2 36/193 mutant which contains inactivating mutations in both SH3 domains (lane 7, upper panel). The binding of cbl to GRB2 36/193 mutant detected in transformed cells (lane 7, lower panel), suggests an interaction of GRB2 SH2 domain with a non-contiguous or a novel tyrosine phosphorylated sequence of cbl because cbl does not contain a predicted GRB2 SH2 binding consensus motif. Thus, to con®rm whether GRB2-SH2 domain can bind directly to tyrosine phosphorylated cbl, we performed Far Western analysis using puri®ed GST-GRB2 wt and GRB2 36/193 .
To determine whether the proline rich region of cbl is responsible for interaction with GRB2 SH3 domains, we analysed the binding of wt and mutant GRB2 proteins to the puri®ed proline rich region of cbl (PRcbl). The wt GRB2, GRB2 36 , GRB2
193 and GRB2 36/193 GST-fusion proteins were puri®ed on anity beads, thrombin cleaved, and equal amounts of recombinant, soluble GRB2 proteins incubated with Agaroseimmobilized PR-cbl. All GRB2 constructs, except for the GRB2 36/193 double mutant which lacks both functional SH3 domains, bound to PR-cbl ( Figure  3c ). These in vitro binding studies indicate that the Nand C-terminal GRB2 SH3 domains bind equally well to the isolated proline rich region of cbl. Lysates from parental or Bp210 cells were incubated with 2 mg of GST alone or wt GST-GRB2 fusion protein to anity purify cbl. The bound proteins were resolved by SDS ± PAGE, transferred onto nitrocellulose membrane and probed with anti-cbl antibody to localize the migration of cbl protein.
Membranes were stripped, denatured-renatured, incubated overnight at 48C with soluble wt GST-GRB2 (top panel) or GST-GRB2 36/193 fusion protein (bottom panel), washed and immunoblotted with anti-GST antibody. The immunoreactive bands were visualized simultaneously by chemiluminescence. The mobility of cbl protein is marked. (c) Proline-rich region of c-cbl associates with N-and C-terminal SH3 domains of GRB2. Proline-rich region (aa 498 ± 589) of human c-cbl was expressed in E. coli as GSTfusion protein (GST-PR-cbl). Wild type (lane 3) and mutant (lanes 4 ± 6, as indicated), soluble GRB2 proteins, generated by thrombin cleavage, were incubated with immobilized GST-PR-cbl for 30 min at 48C. Puri®ed GST alone was used as control (lane 2). Bound proteins were resolved by SDS ± PAGE, immunoblotted with anti-GRB2 polyclonal antibodies and immunoreactive bands visualized by chemiluminescence Cbl links PI 3-kinase and p21 ras pathways in BCR/abl transformed cells SK Jain et al
In summary, these ®ndings suggest that the constitutive association of cbl and GRB2 in parental BaF3 cells is mediated by interactions of the prolinerich region of cbl with SH3 domains of GRB2. A novel interaction between GRB2 SH2 domain and tyrosine phosphorylated cbl may partially contribute to the increased in vivo association although, as discussed below, other SH2 domain-containing proteins may provide an additional indirect mechanism for the increase in cbl-GRB2 complex in BCR/abl transformed cells.
Interactions of cbl with p85 and GRB2
PI 3-kinase activity appears to be essential for BCR/ abl induced mitogenesis in hematopoietic cells (Skorski et al., 1995) . Since PI 3-kinase activation could involve interaction with tyrosine-phosphorylated BCR/abl substrate(s), we investigated the binding of p85 with cbl and association with PI 3-kinase activity in parental and BCR/abl transformed cells. As shown in Figure 4a (lanes 2 and 3), anti-cbl antibodies coprecipitated larger amount of p85 from transformed cells than from parental cells, although the same amount of cbl was present in both immune complexes (not shown). The increase in protein-protein interactions was estimated to be +eightfold by laser densitometry. In converse experiments, anti-p85 antiserum immunoprecipitated cbl from transformed cells (Figure 4b ). The cbl protein bound to p85 in transformed cells was highly tyrosine phosphorylated ( Figure 4c ). An increased association of cbl with p85 has been also reported in activated Jurkat and EGF stimulated PC12 cells (Fukazawa et al., 1995; Kim et al., 1995; Meisner et al., 1995; Solto and Cantley, 1996) . These data suggest formation of cbl-p85 complex in parental cells and that this association is signi®cantly increased when cbl is tyrosine phosphorylated in BCR/abl transformed cells.
Because of our novel ®ndings on the increase in cbl-GRB2 interaction in transformed cells and a recent report that p85 can associate with GRB2 SH3 domains in quiescent and PDGF-stimulated cells (Wang et al., 1995) , we examined GRB2-p85 interactions in parental and transformed cells. We found that GRB2 bound to p85 in quiescent cells (Figure 4a , lane 5 and d, lane 1). In contrast to PDGF-stimulated cells, p85-GRB2 complex was enhanced two to fourfold in transformed cells (Figure 4a , lanes 5 and 6). The increase in GRB2-p85 association in transformed cells was con®rmed using anti-p85 antibodies (Figure 4d, lanes 1 and 2) . Thus, cbl-p85, cbl-GRB2, and GRB2-p85 form constitutive complexes in parental cells which are increased in BCR/abl transformed cells.
Binding of GRB2 SH3 domains to p85 proline-rich regions was con®rmed by in vitro studies in the yeasttwo hybrid system (Wang et al., 1995) . However, the interaction of GRB2 with p85 was not enhanced following activation of the PDGF receptor and no increase in GRB2-associated PI 3-kinase activity was found in response to PDGF (ibid). Similar data was reported in insulin-stimulated cells (Skolnik et al., 1993) . These studies suggest that GRB2-p85 complex does not participate in receptor-mediated signaling. Because these data are dierent from our results, we investigated whether GRB2 associates with PI 3-kinase activity and the mechanisms of interaction of GRB2 with p85 in parental and BCR/abl transformed hematopoietic cells. The increased association of p85 with cbl and GRB2 in transformed cells (Figures 2 and 4 ) raised a possibility that BCR/abl expression is also accompanied by an increase in associated PI 3-kinase activity. PI 3-kinase activity was measured in immune precipitates from parental and transformed cells using anti-P-Tyr, anti-GRB2 and anti-cbl antibodies ( Figure 5 ). Because immunoprecipitations from cell lysates may contain variable amounts of PI 4-kinase activity , we measured the formation of PIP 3 product which can only be generated by phosphorylation of PIP 2 on position 3' by PI 3-kinase (Varticovski et al., 1989) . A +20-fold increase in PIP 3 was generated in anti-P-Tyr (lanes 3 and 4) and anti-GRB2 (lanes 5 and 6) immunoprecipitates from transformed cells when compared to parental cells, and a +14-fold increase was measured in association with cbl (lands 7 and 8). These results suggest that, in addition to an increase in protein-protein interactions described above, anti-GRB2 and anti-cbl immunoprecipitates contain activated PI 3-kinase in transformed cells. The smaller increase in PI 3-kinase activity in anti-cbl as compared to anti-P-Tyr or anti-GRB2 antibodies may be due to ineciency of anti-cbl antibodies as determined from analysis of association with p85 ( Figure 4a ) and precleared cell lysates by Western blot (Figure 1 and not shown). An increase in immunoprecipitable PI 3-kinase activity in association with anti-P-Tyr, GRB2 and cbl antibodies has also been reported following activation of the T and B cell receptors, although the changes reported in these cells are less than in our study (Fukazawa et al., 1995; Kim et al., 1995; Meisner et al., 1995; Reedquist et al., 1994) . In addition, we found a +30% increase in the fraction of total cellular PI 3-kinase activity associated with p85 (lanes 1 and 2) which is consistent with the range of intrinsic activation of the enzyme found in BCR/abl transformed hematopoietic cells (Jain et al., 1996) . p85 SH2 and SH3 domains bind to cbl in BCR/abl transformed cells
To determine the sub domains of p85 which bind to cbl, we used p85 GST-fusion constructs. Signi®cantly higher binding of cbl to p85 C-terminal as compared to the N-terminal SH2 domain was observed in transformed cells (Figure 6a , lanes 2 and 3) which is consistent with previous report . The ability of the same preparations of p85 SH2 domains to bind predicted targets was described previously (Jain et al., 1996) . As shown in Figure 6a , lane 4, abl SH2 domain also bound to cbl in BCR/abl transformed cells as was previously reported Sattler et al., 1996) . Binding of the p85 C-SH2 domain to cbl was not observed in parental cells (Figure 6b, lanes 2 and 5) . In contrast, p85 SH3 domain equally precipitated cbl from parental and transformed cells (Figure 6b, lanes 1 and 4) . Speci®city of SH3 domain interaction with cbl was con®rmed by the lack of association of abl and Crk L SH3 domains (Figure 6b, lanes 6 and 7) . These results suggest that p85 SH3 domain provides constitutive interaction of p85 with cbl in quiescent parental cells and that tyrosine phosphorylation of cbl in transformed cells leads to increased association by interaction with p85 SH2 domains.
In summary, data presented in Figures 4, 5 and 6 indicate that (i) p85 SH3 domain provides a stable complex with cbl in quiescent parental cells, (ii) cbl is a major phosphoprotein associated with p85 in BCR/abl transformed cells, (iii) tyrosine phosphorylation of cbl results in binding to SH2 domains of p85 in transformed cells, and (iv) anti-cbl immune complexes contain over 14-fold increase in PI 3-kinase activity in BCR/abl transformed cells.
Mechanism of p85-GRB2 interaction in parental and BCR/abl transformed cells
To examine the molecular basis for GRB2-p85 interactions, we compared the binding of dierent sub domains of GRB2 to p85 in parental and transformed cells. In addition, we investigated the role of GRB2 binding to BCR/abl in these interactions by analysis of BaF3 cells which express p190 BCR/abl a-p85 a-P-Tyr a-GRB2 a-cbl ) (Pendergast et al., 1993) . Binding of GRB2 to BCR/abl is abrogated in cells expressing p190Y177F BCR/abl mutant (Goga et al., 1995 (data not shown); Pendergast et al., 1993) .
Cell lysates from parental or transformed cells were incubated with wt and mutant GST-GRB2 fusion proteins and bound proteins were analysed by Western blotting with anti-p85 antibodies (Figure 7) . The wild type GST-GRB2, GRB2 36 and GRB2 86 precipitated p85 from all cells (Figure 7a, b and c) . GRB2 36/193 mutant, which only has a functional SH2 domain, precipitated p85 equally from wt p210 and p190 BCR/abl transformed cells but not from Bp190 Y177 or parental cells (Figure 7d ). The failure of GRB2 SH2 domain to bind p85 in cells expressing Y177F BCR/abl mutant suggests that GRB2 SH2 domain-p85 interaction seen in Figure 7d , lanes 2 and 3, is indirect and mediated by binding to Y177 of BCR/abl. Because all blots were processed at the same time, we consistently observed interaction of p85 with GST-GRB2 36 mutant which also suggests that the GRB2 C-terminal SH3 domain binds to p85 although a reduced interaction is detected (compare lane 1 in Figure 7a , b and c).
Taken together, these results suggest that constitutive GRB2-p85 association is mediated by GRB2 SH3 domains, whereas GRB2 SH2 domain binding to pY177 in BCR/abl provides an additional point of interaction which may contribute to the increase in GRB2-p85 complex observed in transformed cells.
Adaptor protein GRB2 is not required for recruitment of cbl to BCR/abl
In BCR/abl transformed cells, cbl is phosphorylated and associates with GRB2. Tyrosine phosphorylation of cbl may provide an additional mechanism for increased interactions with the signaling proteins. To determine whether direct binding of GRB2 is required for recruitment of cbl to BCR/abl tyrosine kinase, we analysed whether cbl is phosphorylated and associates with GRB2 in cell lines which express wt p190 and p190Y177F BCR/abl mutant. We found that cbl associates equally well with the wt p190 and Y177F p190 BCR/abl proteins (Figure 8a ). In addition, lack of The association of p85 with speci®c domains of GRB2. WCL protein from parental or BCR/abl transformed Bp210, Bp190, and Bp190 Y177F cells (1.5 mg), (lanes 2 ± 5, respectively) were incubated with wt GST-GRB2 (a), GRB2 86 (b), GRB2 36 (c) or GRB2 36/193 (d) fusion proteins. The bound proteins were resolved on SDS ± PAGE and analysed by Western blotting using anti-p85 antibody. Individual panels were cut from the same membrane and presented in vertical order. Similar results were obtained in three independent experiments. Mobility of p85 as visualized from WCL (lane 1, a) and the migration of molecular weight standards are marked Cbl links PI 3-kinase and p21 ras pathways in BCR/abl transformed cells SK Jain et al GRB2 binding to BCR/abl does not impair tyrosine phosphorylation of cbl (Figure 8b ) although the level of phosphorylation of cbl was slightly higher in wt Bp210 than Bp190 cells. Figure 8c shows that interaction of cbl with GRB2 in Bp190Y177F cells decreased to levels observed in parental cells, and Figure 8d shows that equal amounts of cbl are precipitated in all cell lines. These data suggest that binding of GRB2 to BCR/abl contributes to the increase in GRB2-cbl complex but is not required for interaction of cbl with BCR/abl or tyrosine phosphorylation of cbl.
Discussion
The mechanism of BCR/abl-mediated transformation of hematopoietic cells involves activation of p21 ras (Mandanas et al., 1993) and PI 3-kinase (Jain et al., 1996; Skorski et al., 1995; Varticovski et al., 1991) pathways. Association of the p21 ras adaptor protein, GRB2, with BCR/abl could be mediated either by direct binding to phosphorylated tyrosine at position 177 of BCR (Pendergast et al., 1993) or indirectly via interaction with Shc or other adaptor proteins (Goga et al., 1995; Harrison-Findik et al., 1995) . Direct binding of GRB2 to BCR/abl is not required for hematopoietic cell transformation or activation of the Ras pathway (Goga et al., 1995) . The role of interaction of GRB2 with other signaling proteins in BCR/abl transformed cells is not known.
Activation of the abl kinase in BCR/abl chimera leads to phosphorylation of several intracellular substrates including Shc, CrkL, p21 ras -GAP, STATs and p120 cbl , and their role in BCR/abl-induced transformation has not been fully established Frank and Varticovski 1996; Goga et al., 1995; Harrison-Findik et al., 1995; Ilaria and Van Etten, 1996; Nichols et al., 1994; Oda et al., 1994; Ribon et al., 1996) . The protooncogene cbl was identi®ed in the murine Cas NS-1 retrovirus as v-cbl, a transforming oncogene that induces hematopoietic tumors in mice (Andoniou et al., 1994; Langdon et al., 1989) . Studies from several laboratories implicated p120 cbl in signaling following activation of the T and B cell receptors (Donovan et al., 1994; Meisner et al., 1995; Odai et al., 1995; . Tyrosine phosphorylation of cbl was also reported in response to GM-CSF, erythropoyetin , activation of the CSF-1 (Wang et al., 1996) , Fcg (Marcilla et al., 1995; Tanaka et al., 1995b) , TPO/cmpl , and the CD38 receptors (Kotani et al., 1995) . These ®ndings suggest an important role for cbl in signal transduction. In addition, cbl has been shown to be tyrosine phosphorylated in BCR/abl transformed BCR/abl transformed human and murine cells and associates with BCR/abl (Andoniou et al., 1996; deJong et al., 1995; Ribon et al., 1996; Sattler et al., 1996) . Here we show that cbl is the major tyrosine phosphorylated protein in BCR/abl transformed BaF3 cells and that expression of BCR/abl gene product greatly enhances the constitutive interactions of cbl with GRB2, p85, and PI 3-kinase activity.
Although constitutive interaction of GRB2 with cbl was shown in many cells, this interaction is not increased following tyrosine phosphorylation of cbl in response to activation of the T, B, or cytokine receptors (Donovan et al., 1994; Fukazawa et al., 1995; Kim et al., 1995; Meisner et al., 1995; Odai et al., 1995; . The mechanism of GRB2 association with cbl in resting cells has been investigated in dierent cell types with con¯icting reports. Several studies reported that only the Nterminal SH3 domain of GRB2 binds with cbl, whereas a recent study found binding of both SH3 domains (Buday et al., 1996) . Here we present evidence that both SH3 domains of GRB2 bind to cbl in parental cells and that binding is mediated by the proline rich region of cbl. GRB2 forms a high anity constitutive complex with mSos, the activator of p21 ras GTPase, by binding of the N-terminal SH3 domain of GRB2 to the proline-rich region of mSos (Egan et al., 1993) . If interaction of GRB2 with cbl is limited to the Nterminal SH3 domain, cbl could compete with mSos which could have a negative eect on signal transduction as was deduced from studies in C. elegans (Yoon et al., 1995) . In contrast, if both SH3 domains of GRB2 can bind to cbl, the GRB2 Cterminal SH3 domain may potentially recruit cbl to this multimolecular complex. Previous reports failed to demonstrate mSOS in association with cbl in activated T cells (Fukazawa et al., 1995; Meisner et al., 1995) . Whether mSos is present in GRB2-cbl complex in 4) were resolved by SDS ± PAGE, transferred onto nitrocellulose membrane and probed with monoclonal anti-abl antibodies (a). This blot was subsequently probed with monoclonal 4G10, anti-P-Tyr antibodies (b), and anti-cbl antibodies (d). (c) shows a separate experiment where anti-cbl immunoprecipitates were blotted with monoclonal anti-GRB2 antibodies (same blot was probed with anti-cbl antibodies to assure equal amounts of cbl, not shown). Mobility of each protein as localized from WCL and molecular weight standards are marked Cbl links PI 3-kinase and p21 ras pathways in BCR/abl transformed cells SK Jain et al BCR/abl transformed cells, and whether N-terminal SH3 domain of GRB2 compete for the same binding site on cbl and mSos, requires further study. The binding of GRB2-cbl complex to BCR/abl may also recruit cbl to BCR/abl tyrosine kinase and allow subsequent tyrosine phosphorylation of cbl. We asked whether direct binding of GRB2 to BCR/abl is necessary for association with BCR/abl or tyrosine phosphorylation of cbl. Using cells which express p190Y177F BCR/abl mutant, which is unable to bind to GRB2, we found no change in the interaction of cbl with BCR/abl or tyrosine phosphorylation of cbl. However, the GRB2-cbl complex in these cells decreased to the levels observed in parental cells. These data suggest that GRB2 is not required for recruitment of cbl to BCR/abl. In addition, transformed hematopoietic cells contain two distinct pools of cbl which interact with BCR/abl in a GRB2-dependent and independent manner (see Figure 9) .
We also tested whether GRB2 SH2 domain binding to tyrosine phosphorylated cbl participates in the enhanced formation of GRB2-cbl complex in transformed cells. We found that cbl associates with GRB2 36/193 mutant which has no functional SH3 domains. Direct binding of GRB2 SH2 domain to cbl was con®rmed by Far Western analysis as reported previously in activated T cells . Because cbl sequence (Blake et al., 1991) does not contain a predicted GRB2 SH2 domain binding motif (Batzer et al., 1994; Songyang et al., 1994) , these data suggest that a non-contiguous sequence or a dierent motif mediate this interaction. However, the interaction of GRB2 SH2 domain with cbl is not likely to contribute signi®cantly to the increase in GRB2-cbl complex in vivo for two reasons. First, GRB2 SH2 domain-mediated binding to cbl in vitro is considerably weaker than is the interaction with SH3 domains or p85 SH2 domains. Second, in cells transformed with Bp190Y177F mutant, the association of GRB2 with cbl decreases to levels observed in parental cells in spite of tyrosine phosphorylation of cbl. These data are consistent with the hypothesis that GRB2 links cbl to BCR/abl, although this is not required for tyrosine phosphorylation of cbl or interaction of cbl with BCR/ abl and p85.
The sequence of cbl contains two motifs (YXXP) favorable for abl SH2 domain binding. We and others Sattler et al., 1996) found that abl SH2 domain binds to cbl in transformed cells. Therefore, tyrosine phosphorylated cbl can bind directly to BCR/abl to maintain high levels of phosphorylation of cbl in transformed cells. Other adaptor proteins of the Crk family may also serve as a link to maintain phosphorylated cbl in proximity to BCR/abl. The SH2 domains of Crk bind to tyrosine phosphorylated cbl and the SH3 domain interacts with a proline-rich region of abl (Andoniou et al., 1996; Buday et al., 1996; deJong et al., 1995; Ribon et al., 1996; Salgia et al., 1995; Sattler et al., 1996) . Indeed, Crk SH2 domains may compete with abl since they recognize the same preferred sequence motif.
PI 3-kinase is also a downstream eector of BCR/ abl tyrosine kinase in CML cells, and decreased expression of its regulatory subunit, p85, inhibits growth of CML cells (Skorski et al., 1995) . Enhanced PI 3-kinase activity and accumulation of its enzymatic products occur in BCR/abl transformed cells, but the mechanism of PI 3-kinase activation in CML cells is not known (Harrison-Findik et al., 1995; Jain et al., 1996; Varticovski et al., 1991) . Occupancy of SH2 domains of PI 3-kinase regulatory subunit, p85, by pYXXM motifs-containing proteins is a potent mechanism for PI 3-kinase activation Myers et al., 1992; Rordorf-Nikolic et al., 1995) . Although p85 SH2 domains can bind to the YXXM motif in BCR/abl, we recently demonstrated that abrogation of this interaction does not aect PI 3-kinase activation or BCR/abl mediated mitogenesis in BaF3 cells (Jain et al., 1996) and suggested that proteins other than BCR/abl participate in PI 3-kinase activation and BCR/abl-induced transformation of hematopoietic cells.
The primary sequence of cbl contains two potential p85 SH2 domain binding motifs and this interaction could lead to PI 3-kinase activation in transformed cells. A similar mechanism of catalytic activation for PI 3-kinase and PTP 1C by tyrosine phosphorylated IRS-I and PDGFR, respectively, was reported recently (Pluskey et al., 1995) . We found an increase in the levels of p85 and an increase in over 14-fold in PI 3-kinase activity in anti-cbl immunoprecipitates. Although Shc is also tyrosine phosphorylated and associates with p85 in Bp210 cells, Shc does not contain an YXXM motif and this interaction is mediated by p85 SH3 domain (Harrison-Findik et al., 1995) .
The increase in p85-cbl complex in transformed cells could be mediated by several mechanisms. The constitutive binding of p85 SH3 domain to cbl in quiescent and BCR/abl transformed BaF3 cells has been reported in other cells Meisner et al., 1995; Reedquist et al., 1994; Solto and Cantley, 1996) . Tyrosine phosphorylation of cbl in BCR/abl transformed cells could create new binding sites for p85 SH2 domains. We con®rmed that p85 SH2 domains bind to tyrosine phosphorylated cbl. However, mutational analysis of cbl is required to Figure 9 Schematic model of interactions of cbl with BCR/abl, GRB2 and p85. SH3 domains of GRB2 and p85 bind constitutively to proline-rich motifs in cbl. Autophosphorylation of BCR/abl may provide the initial contact for GRB2 and p85 SH2 domains. These interactions could recruit cbl to BCR/abl tyrosine kinase with subsequent phosphorylation of cbl. Phosphorylation of cbl leads to interactions with SH2 domains of p85, abl and, as shown by others, crk. The GRB2 SH2 domain also interacts weakly with tyrosine phosphorylated cbl. Additional recruitment of GRB2 may occur by binding of GRB2 SH3 domains to p85 (not shown). In the absence of GRB2 binding to BCR/abl, the recruitment of cbl to BCR/abl could be provided by p85 determine which sites are critical for the interaction with p85 SH2 domains and whether these interactions lead to PI 3-kinase activation. In addition, binding of cbl to the C-terminal SH2 domain of p85 was considerably higher than to the N-terminal domain, which was previously reported for cbl and for binding to other tyrosine phosphorylated sequences (Klippel et al., 1992) . While this manuscript was in preparation, association of cbl with p85 and PI 3-kinase activity in p210 BCR/abl transformed cells was reported (Sattler et al., 1996) . In contrast with our results, Sattler et al found no dierence in binding of cbl to either p85-SH2 domains. One explanation for these dierences is that we used less than 1.5 mg of GST-fusion proteins for in vitro binding studies, whereas in similar binding assays, Sattler et al used 20 mg of GST constructs which may saturate the binding capacity of low anity motifs.
Recently, Wang et al demonstrated an association between GRB2 SH3 domain and the proline-rich regions of p85 in resting NIH3T3 cells. This interaction was not enhanced and PI 3-kinase activity was not increased in anti-GRB2 immunoprecipitates following activation of the PDGF receptor (Wang et al., 1995) . No interaction of p85 or PI 3-kinase activity with GRB2 was reported following activation of the insulin receptor although GRB2 and p85 bound to the same intermediate protein, IRS1 (Skolnik et al., 1993) . These data suggest that distinct pools of PI 3-kinase, independent of GRB2, participate in mitogenic signaling in these cells. In contrast to these reports, we found that the constitutive interaction of GRB2 with p85 in parental cells is markedly enhanced in BCR/abl transformed cells with a +20-fold increase in PI 3-kinase activity in GRB2 immunoprecipitates which was equal to the increase in anti-P-Tyr associated PI 3-kinase activity. A recent report in activated T cells demonstrated an increase in association of p85 and PI 3-kinase activity with GRB2 although the mechanisms of these interactions were not de®ned. Previous data suggested that PI 3-kinase is a downstream target for p21 ras (Rodriquez-Viciana et al., 1994) . Therefore, association of PI 3-kinase with GRB2 in transformed hematopoietic cells may participate in activation of PI 3-kinase. Whether this complex contains mSOS or p21 ras is under investigation. Our data suggest that two mechanisms contribute to the enhanced GRB2-p85 complex in transformed cells. One mechanism is by binding of GRB2 and p85 SH2 domains to the BCR/ abl gene product; the other involves interaction of GRB2 and p85 with cbl. Although we found that GRB2 SH2 domain also binds to cbl in transformed cells, this interaction was weak and probably does not signi®cantly contribute to the increase seen in vivo. This is supported by results from our experiments in which a mutant GRB2 protein, which lacks both functional SH3 domains, associated with p85 in p210 or p190 BCR/abl transformed cells but failed to associate with p85 in cells which express Y177F BCR/abl mutant or in parental cells. Figure 9 is a schematic representation of these interactions.
In conclusion, the data presented here show that p120 cbl is a novel intermediate protein which interacts in vivo with p85 and GRB2 in quiescent and BCR/abl transformed cells. The binding of tyrosine phosphorylated cbl to BCR/abl through the abl SH2 domain may bring cbl in proximity to BCR/abl thereby facilitating sustained tyrosine phosphorylation of cbl. Whether tyrosine phosphorylation of cbl in human chronic myelogenous leukemia and BCR/abl transformed cell lines is required for activation of the Ras or PI 3-kinase pathways requires further investigation.
Materials and methods
Cells and cell culture
The BaF3 cell line is a bone marrow-derived murine IL-3-dependent pro-B cell line (Palacios and Steinmetz, 1985) . BaFp210, BaFp190 and BaFp190 Y177F are BaF3-derived stable transformed cell lines expressing the 210 and wt or mutant 190 kDa BCR/abl gene products, respectively and are IL-3-independent (Daley and Baltimore, 1988; Pendergast et al., 1993) . Cells were maintained in RPM1-1640 medium supplemented with 10% (v/v) fetal calf serum. Parental BaF3 cells were grown in 10% (v/v) WEHIconditioned medium as a source of IL-3. All cells were exposed to low serum medium (1% FCS) in the absence of IL-3 for 14 ± 16 h prior to harvest.
Whole cell lysates
Whole cell lysates (WCL) were prepared as previously described (Susa et al., 1992) . Brie¯y, cells were harvested by centrifugation, washed twice with cold PBS and lysed at 2 ± 4610 7 cells/ml of buer containing 1% Nonidet P-40, 50 mM HEPES pH 7.5, 10% glycerol, 0.5 mM EDTA, 5 mM Na 3 VO 4 and protease inhibitors (10 mg ml 71 leupeptin and aprotinin, and 5 mg ml 71 pepstatin and PMSF). After incubation on ice for 10 min, lysates were centrifuged at 12 000 g and the clear supernatants thus obtained were stored at 7708C until further analysis.
Antibodies
Anti-human p120 cbl rabbit antisera R2 was raised against a GST fusion protein and anity puri®ed (Blake et al., 1991; Bowtell and Langdon, 1995) . Monoclonal and polyclonal anti-p85 antibodies which recognize a and b isoforms of p85, and monoclonal anti-P-Tyr (4G10) antibodies were purchased from UBI (NY, USA). Polyclonal anti-GRB2, and monoclonal anti-GST antibodies were from Santa Cruz Biotechnology Inc. (CA, USA) ; the monoclonal antiabl antibody, 2421, was from Oncogene Science (NY, USA).
Expression, puri®cation and thrombin cleavage of GST-fusion proteins p85 C-and N-terminal SH2 and SH3 domain constructs in pGEX vector were expressed as GST-fusion proteins in E. coli (gift of B Schahausen, Tufts University Medical School, Boston). The wild type GRB2, GRB2 36 , GRB2 86 , GRB2 193 , GRB2 36/193 , Abl-SH2 and SH3 domain GSTfusion constructs were a kind gift from B Mayer (Children's Hospital, HMS, Boston). GRB2 36 and GRB2
193 contain a non-functional N-and C-terminal SH3 domains, respectively; GRB2 36/193 has point mutations in both SH3 domains and the GRB2 86 has a non-functional SH2 domain (Tanaka et al., 1995a) . The proline-rich region of human p120 cbl (PR-cbl, amino acids 498 ± 589) was subcloned in pGEX-2T plasmid and expressed in E. coli. Bacteria were grown at 378C to OD 600 0.4, the target proteins were induced in 250 mM IPTG for 2 ± 4 h and puri®ed from bacterial lysates using glutathione Agarose 4B beads (Sigma) as described (Smith and Johnson, 1988 ). An aliquot of puri®ed GST-fusion proteins was analysed by SDS ± PAGE to assess the quantity and purity.
For thrombin cleavage, 5 ± 10 mg of fusion proteins immobilized on glutathione Agarose were suspended in 100 ml of PBS containing 5 ± 10 U of human thrombin for 30 min at room temperature. At the end of the reaction, PMSF was added at a ®nal concentration of 1 mM, the cleaved proteins were collected in the supernatant and used immediately or stored at 7708C.
Immunoprecipitations, binding assays, Western blotting and Far-Western blotting
For immunoprecipitations, whole cell lysates were incubated with appropriate antibodies for 2 h at 48C followed by addition of 40 ml of protein A-Agarose (Sigma) for 45 min. Immune complexes were collected by centrifugation and washed ®ve times with 16PBS, 36TNE (10 mM Tris/HCl, pH 7.4, 100 mM NaCl, 1 mM EDTA) and once in PBS. Immunoprecipitates were used for the PI 3-kinase assay or denatured by boiling for 3 min in gel loading buer and resolved by SDS-polyacrylamide gels.
For binding assays, WCLs or thrombin cleaved recombinant proteins were incubated with 1 ± 2 mg of appropriate (as indicated in Figure legends) immobilized GST-fusion proteins at 48C for 30 min (for SH3 domains) or 2 h (for SH2 domains). The fusion protein complexes were subsequently washed 36 with HNTG buer (20 mM HEPES, pH 7.5, 150 mM NaCl, 0.1% Triton X-100, 10% glycerol, 50 mM NaF, 1 mM Na 3 VO 4 ) . Bound proteins were separated on SDS ± PAGE and identi®ed by Western blotting.
Proteins resolved on SDS ± PAGE were electrophoretically transferred onto nitrocellulose membranes (Pharmacia, Piscataway, NJ, USA). The membranes were blocked in PBST (0.2% Tween-20)/7% non-fat dry milk and 2% BSA for 1 h and probed with antibodies as indicated in the Figure  legends . Immunoreactive bands were visualized by using ECL reagents (Amersham, Illinois, USA).
For Far-Western analysis, nitrocellulose membranes were denatured in buer A plus 6 M guanidine HCl (buer A, 50 mM Tris HCl; pH 7.9, 25 NaCl, 5 mM MnCl 2 5 mM MgCl 2 and 1 mM DTT) at 48C for 20 min on a rocking platform and then renatured gradually in buer A. The membranes were subsequently washed with PBS-T, blocked (as described above) and incubated overnight with fusion proteins (1 mg/ml in 1% BSA) at 48C. After washing thoroughly, membranes were probed with antibodies as indicated in the Figure  legends and immunoreactive bands were visualized by using ECL reagents.
PI 3-kinase assay
In vitro Pl 3-kinase activity was measured in whole cell extracts and immune complexes as described (Susa et al., 1992) . The reaction mixture contained sonicated standard phospholipid mixtures (equal amounts of PS, PI and PIP 2 ) at a ®nal concentration of 0.2 mg/ml in 50 ml reaction. Reaction was carried out at 378C for 20 min after addition of ATP to a ®nal concentration of 150 mM and 15 mCi of [g-32 P]ATP (4 mCi/nMol, Dupont, NEN). Reaction was terminated by addition of Methanol:1 N HCl (1 : 1). Phospholipids were extracted twice within the same volume of chloroform, separated by TLC and visualized by autoradiography. The enzymatic activity was expressed as pmoles of phosphate incorporated into PI 3, 4, 5-P 3 and presented as fold increase comparing with anti-P-Tyr immunoprecipitable activity from parental cells.
